Short answer
AMICUS THERAPEUTICS, INC. (FOLD) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholder approval secured: 234.6M shares (99.9% of votes cast) approved BioMarin acquisition of Amicus, clearing key merger condition.
AMICUS THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholder approval secured: 234.6M shares (99.9% of votes cast) approved BioMarin acquisition of Amicus, clearing key merger condition
- FTC early termination granted Feb 11, 2026: U.S. antitrust clearance already obtained
- Remaining hurdles: European and Japanese regulatory approvals plus other customary closing conditions
- Deal expected to close Q2 2026; merger agreement dated Dec 19, 2025 with BioMarin as acquirer via wholly owned subsidiary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AMICUS THERAPEUTICS, INC. 8-K filings
Get the next FOLD 8-K as it lands
Follow FOLD for push alerts, or ask the research agent what this filing means.